IFP Advisors Inc Increases Stake in Sanofi (NASDAQ:SNY)

IFP Advisors Inc raised its stake in shares of Sanofi (NASDAQ:SNY) by 17.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,132 shares of the company’s stock after acquiring an additional 313 shares during the period. IFP Advisors Inc’s holdings in Sanofi were worth $103,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of SNY. Jennison Associates LLC lifted its stake in Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after acquiring an additional 1,424,289 shares during the period. DAVENPORT & Co LLC lifted its stake in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after acquiring an additional 664,455 shares during the period. JPMorgan Chase & Co. lifted its stake in Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. Institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $57.70 on Wednesday. The firm’s 50 day moving average price is $52.00 and its 200-day moving average price is $52.64. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $146.43 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts expect that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several research analyst reports. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.